Laura Niccoli

Prato, 59100, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Ixekizumab for the treatment of psoriatic arthritis: an Italian multicentric retrospective observational study.

Ixekizumab for the treatment of psoriatic arthritis: an Italian multicentric retrospective observational study.

Journal: Scientific reports

Published: March 05, 2025

Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre study.

Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre study.

Journal: Clinical and experimental medicine

Published: January 13, 2025

Secukinumab for the Treatment of Axial Spondyloarthritis: Long-Term Real-Life Data from Five Italian Referral Centers.

Secukinumab for the Treatment of Axial Spondyloarthritis: Long-Term Real-Life Data from Five Italian Referral Centers.

Journal: Journal of personalized medicine

Published: September 18, 2024

Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65).

Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65).

Journal: Journal of personalized medicine

Published: May 03, 2024

ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice.

ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice.

Journal: Journal of personalized medicine

Published: August 01, 2023

Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study.

Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: July 12, 2022

Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements.

Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements.

Journal: Expert opinion on drug safety

Published: December 23, 2021

Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.

Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.

Journal: Drugs

Published: October 17, 2020

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.

Journal: Science advances

Published: August 24, 2020

Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases.

Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases.

Journal: Expert opinion on drug safety

Published: June 20, 2020

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study.

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study.

Journal: The Journal of infection

Published: June 19, 2020

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.

Journal: The Journal of infection

Published: April 11, 2020

Showing 1-12 of 38

Last Updated: 09/26/2026